FRACTYL HEALTH INC. O.N. Aktie

Fractyl Health presented at the Canaccord growth conference its strategy to develop one-time metabolic treatments that address weight and root causes of diabetes. Lead program Revita showed sustained weight maintenance after GLP‑1 therapy in pilot studies and is now running a 300‑patient, approval‑relevant trial with initial 6‑month data due in early Q4; a regulatory submission based on those data is planned by year‑end. Rejuva, a gene‑therapy candidate for endogenous GLP‑1 production, received IND clearance and is approaching first-in-human use. Fractyl plans to commercialize through roughly 200–400 centers of excellence rather than a broad rollout; success depends on clinical and regulatory milestones. » Plus sur de.investing.com

Fractyl Health reported adjusted EPS of -$0.16, beating the estimate of -$0.25 (by 36%), driven by lower R&D spending and reduced cash burn. Operating cash consumption was about $16 million for the quarter; cash and cash equivalents of $47.1 million are expected by management to be sufficient into early 2027. No capital raises are planned ahead of the approval‑relevant Revita/REMAIN‑1 data. The market reaction was muted (stock at $0.68) as investors are primarily awaiting the upcoming REMAIN‑1 top‑line data in early Q4 2026 and a possible de‑novo filing at quarter end. » Plus sur de.investing.com

Fractyl Health reports from the REMAIN‑1 midpoint cohort that a single Revita‑DMR procedure reduced weight regain after one year by about 40% versus sham treatment. Participants with complete duodenal ablation >14 cm retained roughly 81% of their GLP‑1‑induced weight loss versus 48% in the control group; a subgroup with ≥17.5% initial loss retained about 84% versus 46%. The responder rate for weight maintenance was 73% overall and 91% for complete ablation; no serious procedure‑ or device‑related adverse events occurred. Fractyl expects first six‑month data from the pivotal cohort in early Q4 2026 and is targeting a possible De‑Novo submission to the FDA by the end of Q4 2026. » Plus sur de.investing.com